EUS-guided portal injection chemotherapy for treatment of hepatic metastases: Feasibility in the acute porcine model

Douglas Orrick Faigel, Douglas F. Lake, Tracy L. Landreth, Catherine C. Kelman, Ronald J Marler

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background and Aims Direct injection of chemotherapy into the portal vein for treatment of liver metastases may increase hepatic tissue levels while decreasing systemic levels and toxicities. We aimed to evaluate EUS-guided portal injection chemotherapy (EPIC) by using drug-eluting microbeads or nanoparticles and compare it with systemic injection. Methods We conducted a comparative feasibility trial in the acute porcine model (24 anesthetized pigs). Pigs were treated with irinotecan, doxorubicin, or albumin-bound paclitaxel nanoparticles (n = 8/group). Within each group, pigs were treated with EPIC or a systemic intravenous injection of drug and saline solution into the portal vein (n = 4/treatment). Irinotecan or doxorubicin were loaded onto microbeads for EPIC treatment only. We examined drug levels in tissue (1 hour) and plasma (15 minutes). Results EUS-guided access and injection was successful in all animals. EPIC with irinotecan-loaded microbeads showed nearly double the hepatic concentration compared with systemic injection (6242 vs 3692 ng/g) and almost half the systemic levels. EPIC with doxorubicin-loaded microbeads showed a 5-fold increase in hepatic levels (35,450 vs 6930 ng/g) and a 30-fold decrease in cardiac levels (153 vs 4805 ng/g) compared with systemic administration (P

Original languageEnglish (US)
Pages (from-to)444-446
Number of pages3
JournalGastrointestinal Endoscopy
Volume83
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

irinotecan
Swine
Neoplasm Metastasis
Drug Therapy
Injections
Liver
Microspheres
Doxorubicin
Therapeutics
Portal Vein
Nanoparticles
Pharmaceutical Preparations
Sodium Chloride
Intravenous Injections

ASJC Scopus subject areas

  • Gastroenterology
  • Radiology Nuclear Medicine and imaging

Cite this

EUS-guided portal injection chemotherapy for treatment of hepatic metastases : Feasibility in the acute porcine model. / Faigel, Douglas Orrick; Lake, Douglas F.; Landreth, Tracy L.; Kelman, Catherine C.; Marler, Ronald J.

In: Gastrointestinal Endoscopy, Vol. 83, No. 2, 01.02.2016, p. 444-446.

Research output: Contribution to journalArticle

Faigel, Douglas Orrick ; Lake, Douglas F. ; Landreth, Tracy L. ; Kelman, Catherine C. ; Marler, Ronald J. / EUS-guided portal injection chemotherapy for treatment of hepatic metastases : Feasibility in the acute porcine model. In: Gastrointestinal Endoscopy. 2016 ; Vol. 83, No. 2. pp. 444-446.
@article{4ca30535b1dc466597a5247a2596da3f,
title = "EUS-guided portal injection chemotherapy for treatment of hepatic metastases: Feasibility in the acute porcine model",
abstract = "Background and Aims Direct injection of chemotherapy into the portal vein for treatment of liver metastases may increase hepatic tissue levels while decreasing systemic levels and toxicities. We aimed to evaluate EUS-guided portal injection chemotherapy (EPIC) by using drug-eluting microbeads or nanoparticles and compare it with systemic injection. Methods We conducted a comparative feasibility trial in the acute porcine model (24 anesthetized pigs). Pigs were treated with irinotecan, doxorubicin, or albumin-bound paclitaxel nanoparticles (n = 8/group). Within each group, pigs were treated with EPIC or a systemic intravenous injection of drug and saline solution into the portal vein (n = 4/treatment). Irinotecan or doxorubicin were loaded onto microbeads for EPIC treatment only. We examined drug levels in tissue (1 hour) and plasma (15 minutes). Results EUS-guided access and injection was successful in all animals. EPIC with irinotecan-loaded microbeads showed nearly double the hepatic concentration compared with systemic injection (6242 vs 3692 ng/g) and almost half the systemic levels. EPIC with doxorubicin-loaded microbeads showed a 5-fold increase in hepatic levels (35,450 vs 6930 ng/g) and a 30-fold decrease in cardiac levels (153 vs 4805 ng/g) compared with systemic administration (P",
author = "Faigel, {Douglas Orrick} and Lake, {Douglas F.} and Landreth, {Tracy L.} and Kelman, {Catherine C.} and Marler, {Ronald J}",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.gie.2015.08.064",
language = "English (US)",
volume = "83",
pages = "444--446",
journal = "Gastrointestinal Endoscopy",
issn = "0016-5107",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - EUS-guided portal injection chemotherapy for treatment of hepatic metastases

T2 - Feasibility in the acute porcine model

AU - Faigel, Douglas Orrick

AU - Lake, Douglas F.

AU - Landreth, Tracy L.

AU - Kelman, Catherine C.

AU - Marler, Ronald J

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Background and Aims Direct injection of chemotherapy into the portal vein for treatment of liver metastases may increase hepatic tissue levels while decreasing systemic levels and toxicities. We aimed to evaluate EUS-guided portal injection chemotherapy (EPIC) by using drug-eluting microbeads or nanoparticles and compare it with systemic injection. Methods We conducted a comparative feasibility trial in the acute porcine model (24 anesthetized pigs). Pigs were treated with irinotecan, doxorubicin, or albumin-bound paclitaxel nanoparticles (n = 8/group). Within each group, pigs were treated with EPIC or a systemic intravenous injection of drug and saline solution into the portal vein (n = 4/treatment). Irinotecan or doxorubicin were loaded onto microbeads for EPIC treatment only. We examined drug levels in tissue (1 hour) and plasma (15 minutes). Results EUS-guided access and injection was successful in all animals. EPIC with irinotecan-loaded microbeads showed nearly double the hepatic concentration compared with systemic injection (6242 vs 3692 ng/g) and almost half the systemic levels. EPIC with doxorubicin-loaded microbeads showed a 5-fold increase in hepatic levels (35,450 vs 6930 ng/g) and a 30-fold decrease in cardiac levels (153 vs 4805 ng/g) compared with systemic administration (P

AB - Background and Aims Direct injection of chemotherapy into the portal vein for treatment of liver metastases may increase hepatic tissue levels while decreasing systemic levels and toxicities. We aimed to evaluate EUS-guided portal injection chemotherapy (EPIC) by using drug-eluting microbeads or nanoparticles and compare it with systemic injection. Methods We conducted a comparative feasibility trial in the acute porcine model (24 anesthetized pigs). Pigs were treated with irinotecan, doxorubicin, or albumin-bound paclitaxel nanoparticles (n = 8/group). Within each group, pigs were treated with EPIC or a systemic intravenous injection of drug and saline solution into the portal vein (n = 4/treatment). Irinotecan or doxorubicin were loaded onto microbeads for EPIC treatment only. We examined drug levels in tissue (1 hour) and plasma (15 minutes). Results EUS-guided access and injection was successful in all animals. EPIC with irinotecan-loaded microbeads showed nearly double the hepatic concentration compared with systemic injection (6242 vs 3692 ng/g) and almost half the systemic levels. EPIC with doxorubicin-loaded microbeads showed a 5-fold increase in hepatic levels (35,450 vs 6930 ng/g) and a 30-fold decrease in cardiac levels (153 vs 4805 ng/g) compared with systemic administration (P

UR - http://www.scopus.com/inward/record.url?scp=84955208488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955208488&partnerID=8YFLogxK

U2 - 10.1016/j.gie.2015.08.064

DO - 10.1016/j.gie.2015.08.064

M3 - Article

C2 - 26358330

AN - SCOPUS:84955208488

VL - 83

SP - 444

EP - 446

JO - Gastrointestinal Endoscopy

JF - Gastrointestinal Endoscopy

SN - 0016-5107

IS - 2

ER -